{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/regenxbio-announces-first-patient-dosed-in-phase-iibiii-naavigate-trial-of-surabgene-lomparvovec-in-diabetic-retinopathy-company-to-receive-100-million-milestone-302812721.html", "message": "News view counter 820242 successfully enlarged"}